Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from CASI Pharmaceuticals ( (CASIF) ).
CASI Pharmaceuticals, Inc. reported that its ordinary shares began trading on the OTCQB market under the ticker symbol CASIF on April 14, 2026. The move broadens access for U.S. investors and may enhance liquidity and visibility for the clinical-stage biopharmaceutical company as it advances development of its CID-103 antibody program.
The most recent analyst rating on (CASIF) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASIF Stock Forecast page.
Spark’s Take on CASIF Stock
According to Spark, TipRanks’ AI Analyst, CASIF is a Neutral.
The score is primarily weighed down by poor financial performance (declining revenue, ongoing losses, negative and worsening free cash flow, and very high leverage). Technicals are somewhat improved in the short term but remain weak versus longer-term trend levels, while valuation is difficult to support due to negative earnings and no dividend yield data.
To see Spark’s full report on CASIF stock, click here.
More about CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing CID-103, an anti-CD38 monoclonal antibody. The company targets indications in organ transplant rejection and autoimmune diseases, positioning itself in the immunology and specialty biologics segment of the healthcare market.
Average Trading Volume: 209,583
Technical Sentiment Signal: Sell
Current Market Cap: $2.32M
For an in-depth examination of CASIF stock, go to TipRanks’ Overview page.